Efficacy of glucocorticoids treatment in recurrent embryo implantation failure

Recurrent implantation failure (RIF) poses a significant challenge in treating infertility. RIF can stem from various factors, commonly involving immune issues. Recent literature suggests that glucocorticoids (GCs) can effectively inhibit immune responses in RIF patients. However, a recent multicenter randomized controlled trial found that oral prednisone did not enhance live birth rates in RIF cases. Despite their potential benefits, the diversity in dosage regimens and treatment protocols highlights the need for further research to establish standardized guidelines and ensure long-term safety. This review explores the use of GCs treatments for RIF, including their use alone and in combination with other medications. It emphasizes the necessity for solid evidence to determine the effectiveness and safety of these treatments. Future studies should focus on defining optimal dosages, treatment durations, and administration methods tailored to different RIF patient profiles. Moreover, well-designed randomized trials are crucial to assess the efficacy and risks associated with GCs in treating RIF.